Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Pfizer

Share:
Related PFE
Carl Icahn's Track Record In Big Pharma
Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
A Dividend Portfolio Built From The World's Best Dividend ETFs (Seeking Alpha)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Pfizer (NYSE: PFE), but slightly lowered its price target from $28.00 to $27.00.

Jefferies noted, “The 5% revenue miss in Q3'12 was forgiven to a degree as Lipitor phasing was partly to blame and EPS was still delivered through financial engineering. Lighter than expected Prevnar-13 and Enbrel sales were more concerning, though we now have the US launches of tofacitinib and hopefully Eliquis within the next 3-6 months to look forward to. New product launches, share repurchases and restructuring drive near term upside in our view.”

Pfizer closed on Friday at $24.16.

Latest Ratings for PFE

DateFirmActionFromTo
Dec 2016GuggenheimInitiates Coverage OnNeutral
Nov 2016BarclaysUpgradesEqual-WeightOverweight
Nov 2016BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!